Antidepressant Risk in Personal Injury Claims
Navigate SSRI and SNRI use in your claims management
Published: 3 April 2026 | Updated: 3 April 2026
Why Antidepressants Matter in Your Claims
Antidepressants are among the most commonly prescribed medications in Australia and New Zealand, particularly in personal injury claims where psychological injury often accompanies physical trauma. As an insurer, you need to understand how these medications affect claimant recovery, work capacity, and long-term outcomes. Antidepressants can genuinely support recovery, but inappropriate prescribing, prolonged use, or inadequate review can mask underlying issues and delay return to work.
The risk isn't always obvious. A claimant on an appropriate SSRI dose may progress well; the same medication at an inflated dose, combined with other CNS depressants, becomes a barrier to recovery. Your role is to ensure medications serve the claim, not derail it.
Understanding SSRIs and SNRIs
Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs) are the frontline pharmacological treatments for depression and anxiety. In the personal injury context, they're typically prescribed for post-traumatic stress disorder (PTSD), adjustment disorder, or clinical depression secondary to injury.
Common SSRIs in Claims
- Sertraline (Zoloft): Fast onset, generally well-tolerated, common first choice
- Citalopram (Cipramil): Popular in older adults, dose-limited due to QT prolongation risk above 40mg daily
- Escitalopram (Lexapro): Isomer of citalopram, similar profile, dose capped at 20mg daily
- Paroxetine (Aropax): More sedating, discontinuation syndrome risk if not tapered carefully
- Fluoxetine (Prozac): Longer half-life, can accumulate, withdrawal effects less pronounced
Common SNRIs in Claims
- Venlafaxine (Effexor XR): More activating, useful if sedation is a concern; requires careful dose escalation
- Duloxetine (Cymbalta): Approved for chronic pain, dual benefit in mixed pain-mood presentations
Clinical Risk Factors in Claims
Polypharmacy and CNS Depression
Antidepressants combined with benzodiazepines, Z-drugs (zolpidem, zopiclone), or opioids amplify CNS depression. This significantly impairs work capacity, increases fall and accident risk, and can mask genuine recovery. A claimant on sertraline 100mg, diazepam 10mg, and codeine 30mg three times daily presents compounded sedation that antidepressant dose optimisation alone won't resolve.
Dose Escalation Without Review
Some prescribers escalate doses without structured reassessment, assuming higher doses equal better outcomes. In your claims context, dose escalation should trigger a medication review. A claimant on sertraline 200mg (double the standard range) needs clarity on whether this reflects genuine pharmacological optimisation or therapeutic drift.
Duration Beyond Evidence
Most guidelines recommend 12 months of antidepressant therapy post-diagnosis, with tapering considered at that point if recovery is solid. Claims that remain on antidepressants for 3, 4, or 5 years without documented therapeutic rationale or recent review warrant formal assessment. Prolonged use can reinforce illness identity and reduce engagement with active rehabilitation.
Inadequate Psychological Support
Antidepressants work best alongside evidence-based psychological therapy. A claimant on medication alone without concurrent psychotherapy, cognitive-behavioural therapy (CBT), or occupational therapy often plateaus. If your claimant's psychiatrist hasn't documented psychological treatment in 12 months, that's a review trigger.
Medication Review Triggers
You should refer for a pharmacy review when:
| Clinical Scenario | Action |
|---|---|
| SSRI/SNRI combined with benzodiazepine, Z-drug, or opioid | Refer for deprescribing review to reduce CNS depression |
| Dose escalation without documented therapeutic rationale | Refer to confirm dose aligns with clinical guidelines |
| Antidepressant use beyond 18 months without recent psychiatric review | Refer to assess continuation vs. tapering plan |
| SSRI/SNRI monotherapy without concurrent psychology support | Refer to confirm psychological strategy and medication alignment |
| Claimant reports sedation, cognitive dulling, or sexual dysfunction | Refer to assess if medication side effects are impacting recovery |
| Multiple antidepressant changes within 12 months | Refer to stabilise regimen and clarify outcome expectations |
Side Effects and Work Capacity
Common SSRI and SNRI side effects include nausea (usually transient), sexual dysfunction, weight gain, and emotional blunting. In the first 2 to 4 weeks, some claimants experience increased anxiety or restlessness. This is often addressed by dose titration or temporary anxiolytic support, not medication abandonment.
However, persistent side effects can derail claims. A claimant whose dose of sertraline causes significant sexual dysfunction may disengage from treatment and therapy. An insurer aware of this can work with the treating doctor to consider alternative SSRIs or addition of agents like bupropion that mitigate sexual side effects. Proactive management here prevents treatment failure.
Emotional Blunting and Recovery
Some claimants on SSRIs report "feeling flat" or disconnected. In the injury recovery context, this can impair motivation for rehabilitation and return-to-work activities. This requires careful dose review and occasionally a switch to agents less likely to induce blunting. The goal is symptom control without functional suppression.
Tapering and Discontinuation
Abrupt cessation of SSRIs and SNRIs causes discontinuation syndrome: anxiety, irritability, dizziness, headache, and sometimes rebound mood symptoms. Responsible tapering typically occurs over 4 to 12 weeks, depending on the agent and duration of use. Fluoxetine, with its long half-life, requires slower tapering than paroxetine, which carries higher discontinuation risk.
In your claims context, ensure any medication cessation is planned, gradual, and accompanied by psychological support or increased therapy frequency. A claimant stopped abruptly on an SSRI may experience severe anxiety or mood deterioration that stalls recovery and generates new claims complications.
Recommended Review Workflow
Step 1: Request pharmacy review when antidepressant use extends beyond 18 months, is combined with CNS depressants, or claimant reports persistent side effects or no progress.
Step 2: Clarify clinical rationale with prescriber. Request documentation of recent psychiatric assessment, response to medication, and plan for continuation or tapering.
Step 3: Assess psychological support. Confirm concurrent therapy; if absent, request addition or referral.
Step 4: Align with rehabilitation. Ensure medication strategy supports, not hinders, work-capacity goals and active rehabilitation.
Step 5: Monitor and review. Schedule follow-up pharmacy review at 6 months to confirm ongoing benefit and assess readiness for dose reduction or cessation.
Common Misunderstandings
Myth 1: "Higher doses work faster." Reality: Standard doses are evidence-based. Escalation beyond guidelines rarely accelerates response and increases side-effect risk.
Myth 2: "Medication alone treats PTSD." Reality: Antidepressants reduce symptom severity; psychological therapies like trauma-focused CBT or EMDR address the underlying trauma. Medication without therapy often plateaus.
Myth 3: "Once on an antidepressant, the claimant needs it forever." Reality: Guidelines support planned cessation after 12 months of recovery. Indefinite use should be intentional, not default.
Myth 4: "Changing medications always makes things worse." Reality: Strategic switches to manage side effects, resistance, or dose-related complications are standard practice and often improve outcomes.
Your Role as an Insurer
You're not prescribing. Your role is to ensure medication use aligns with evidence, supports recovery, and is regularly reviewed. Armed with knowledge of antidepressant risk and benefit, you can ask the right questions: Is this dose justified? Where's the psychological support? Why has the claimant been on medication for 4 years without tapering discussion? Does the medication regimen support return to work?
Pharmacist-led medication reviews place an evidence-based lens on these questions, helping you make informed decisions about continued funding, care coordination, and expected claimant outcomes.
Is your claimant on a long-term antidepressant with no recent review?
IMM's medication reviews assess whether SSRI and SNRI use aligns with recovery goals and guides strategic deprescribing or optimisation. We work with your team to ensure psychiatric medication supports, not delays, claimant progress.
Request a Medication Review
